US 11433097
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
granted A61KA61K2239/38A61K2239/57
Quick answer
US patent 11433097 (Methods of using tumor infiltrating lymphocytes in double-refractory melanoma) held by Iovance Biotherapeutics, Inc. expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2239/38, A61K2239/57, A61K35/00, A61K40/11